Di Pasquale Pietro, Cannizzaro Sergio, Giambanco Francesco, Scalzo Sebastiano, Tricoli Giuseppe, Fasullo Sergio, Paterna Salvatore
Division of Cardiology, "Paolo Borsellino," G.F. Ingrassia Hospital, Palermo, Italy.
J Cardiovasc Pharmacol. 2005 Jul;46(1):83-8. doi: 10.1097/01.fjc.0000164089.96445.d8.
The study was aimed to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI <2 hours, and in patients initially successfully treated with pharmacological therapy and delayed PCI (12-72 hours). All patients had to have successful reperfusion, to receive the combination of a standard abciximab infusion plus half dose rtPA. Similar results were observed in both groups. Delayed PCI group showed a favorable trend in restenosis and bleedings (ns) and a significant reduced angiographic evidence of thrombus formation in IRA. Our very preliminary data suggest the safety and possible use of delayed facilitated PCI in patients with STEMI. The studied patients have successful reperfusion and TIMI-3 flow and our data may not apply to patients with TIMI 0-2 flow.